Organization | South China Children's Leukemia Group

South China Children's Leukemia Group Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial

2011

NCT02200978

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 4 Trials (7)

arsenic trioxide (trisenox) (1 trial)

cytarabine (cytosar-u) (1 trial)

indigo (1 trial)

mercaptopurine (purinethol) (1 trial)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (1 trial)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 4)

Leukemia, Promyelocytic, Acute (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 1
# of Trial APIs: 7